Profile
CHRO NVO VRTX REGN SGEN ARGX
Company Name Chromocell Therapeutics Corporation Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $11.45M $362.58B $107.38B $74.92B $43.15B $39.83B
Employees 0.00K 71.88K 5.40K 14.17K 3.26K 1.15K
CEO Mr. Francis Knuettel II, M.B.A. Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Ratings
CHRO NVO VRTX REGN SGEN ARGX
Quant Rating Score 2 3 4 4 3 1
Quant Rating Sell Neutral Buy Buy Neutral Strong Sell
Trading
CHRO NVO VRTX REGN SGEN ARGX
Last Close $0.96 $83.07 $416.96 $693.23 $228.74 $659.81
High 52 $4.03 $146.91 $516.74 $1201.76 $228.74 $670.4
Low 52 $0.54 $81.18 $392.81 $690.87 $228.74 $356.01
Price vs. 52 Week High -76.18 % -43.46 % -19.31 % -42.32 % 0 % -1.58 %
Price vs. 52 Week Low 77.78 % 2.33 % 6.15 % 0.34 % 0 % 85.33 %
Total Return
CHRO NVO VRTX REGN SGEN ARGX
1 Month Return 54.96 % -23.09 % -11.14 % -6.32 % 0 % 3.37 %
3 Month Return 24.76 % -29.73 % -16.4 % -30.53 % 0 % 21.44 %
6 Month Return -17.95 % -38.66 % -14.62 % -36.14 % 0 % 42.38 %
9 Month Return -51.76 % -33.29 % 6.07 % -23.08 % 0 % 80.18 %
YTD Return 49.77 % -3.43 % 3.54 % -2.68 % 0 % 7.29 %
1 Year Return 0 % -22.15 % -3.87 % -25.39 % 0 % 77.1 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
CHRO NVO VRTX REGN SGEN ARGX
Dividend Yield Percentage (TTM) - 1.67 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.25 % -2.62 % 4.88 % -2.27 % -2.22 %
Dividend Per Share (TTM) - 9.9 % - - - -
Payout Ratio (TTM) - 46.6 % - - - -
Growth
CHRO NVO VRTX REGN SGEN ARGX
Asset Growth 75.02 % 30.35 % 25.23 % 13.23 % -1.21 % 44.93 %
Gross Profit Growth -558.47 % 32.32 % 9.64 % 6.49 % 22.93 % 190.7 %
Revenue Growth - 31.26 % 10.51 % 7.76 % 24.65 % 198.56 %
Revenue 3 Year -100 % 90.03 % 60.36 % 55.67 % 91.56 % 2071.96 %
Revenue 5 Year -100 % 123.63 % 219.55 % 110.3 % 215.48 % 3041.46 %
Revenue 10 Year -100 % 65.69 % 610.45 % 549.62 % 494.04 % 9009.53 %
EBIT Growth -196.02 % 37.11 % 0 % -14.6 % 10.13 % 40.94 %
Net Income Growth -200.2 % 50.71 % 8.96 % -8.87 % 9.51 % 58.42 %
Net Income 3 Yeari Growth Per Share -1017.31 % 106.26 % 34.59 % 13.48 % -763.59 % 64.01 %
Net Income 5 Yeari Growth Per Share -1017.31 % 133.27 % 70.33 % 74.02 % -276.93 % -143.65 %
Net Income 10 Yeari Growth Per Share -1017.31 % 98.1 % 809.6 % 871.12 % -624.16 % -857 %
Operating Income Growth -196.02 % 37.11 % 0 % -14.6 % 10.13 % 40.94 %
Operating Cash Flow Growth (CFG) 37.4 % 38.06 % -14.35 % -8.39 % 9.07 % 51.28 %
Operating 3 Year CFG 72.94 % 117.73 % 9.63 % 76.95 % -147.99 % 21.71 %
Operating 5 Year CFG 72.94 % 162.84 % 174.78 % 125.17 % -195.86 % -329.63 %
Operating 10 Year CFG 72.94 % 150.28 % 6084.35 % 713.56 % -2622.09 % -1280.2 %
EPS Growth -197.67 % 51.88 % 8.33 % -8.54 % 10.81 % 60.46 %
EPS Diluted Growth -197.67 % 52.37 % 8.35 % -9.03 % 10.81 % 60.46 %
Book Value Per Share -73.87 % 28.67 % 25.58 % 15.03 % -9.83 % 38.53 %
Share Holder 3 Year Equity Growth Per Share -80.12 % 74.77 % 104.06 % 137.56 % 33.72 % 93.75 %
Share Holder 5 Year Equity Growth Per Share -80.12 % 121.34 % 291.14 % 219.1 % 220.81 % 318.81 %
Share Holder 10 Year Equity Growth Per Share -80.12 % 49.24 % 1030.79 % 1286.9 % 691.19 % 3654.06 %
Dividend Per Share Growth - 26.56 % - - - -
Dividend 3 Year Growth Per Share - 63.98 % - - - -
Dividend 5 Year Growth Per Share - 79.57 % - - - -
Dividend 10 Year Growth Per Share - 94.94 % - - - -
Debt Growth 134.75 % 4.74 % 44.1 % 0.06 % -23.28 % 60.95 %
Free Cash Flow Growth 37.4 % 9.17 % -16.47 % -17.11 % 3.67 % 51.98 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
CHRO NVO VRTX REGN SGEN ARGX
Gross Profit Margin TTM - 84.66 % 86.1 % 84.42 % 72.37 % 86.82 %
Return on Assets TTM -470.48 % 23.83 % -2.16 % 12.43 % -11.76 % -2.13 %
Return on Equity TTM 581.58 % 86.4 % -2.88 % 16.85 % -16.53 % -2.75 %
Return on Capital Employed TTM 674.27 % 62.74 % -1.72 % 11.85 % -16.87 % -8.98 %
Net Income Per EBT TTM 100 % 79.43 % -184.82 % 93.66 % 100.55 % 167.72 %
EBT Per Ebit TTM 104.6 % 100.52 % -82.68 % 124.1 % 94.01 % 15.76 %
EBIT Per Revenue TTM - 43.84 % -2.96 % 28.92 % -36.09 % -17.08 %
Cash Flow To Debt Ratio TTM -239.51 % 207.5 % -49.48 % 157.08 % -185.98 % -428.57 %
Receivables Turnover TTM - 3.89 6.06 2.27 1.98 3.45
Payables Turnover TTM 2.38 1.72 3.73 4.34 1.54 1.06
Inventory Turnover TTM - 1.09 1.37 0.71 0.65 0.91
Fixed Asset Turnover TTM - 225.8 % 422.11 % 311.93 % 256.83 % 6116.64 %
Asset Turnover TTM - 68.08 % 47.71 % 36.98 % 34.46 % 47.09 %
Operating Cash Flow Per Share TTM -0.95 26.54 -3.27 39.29 -1.12 -2.42
Free Cash Flow Per Share TTM -0.95 15.14 -4.51 31.25 -1.62 -3.52
Cash Per Share TTM 21.67 % 1681.33 % 2528.88 % 9062.44 % 657.5 % 5163.05 %
Operating Cash Flow Sales Ratio TTM - 43.69 % -7.94 % 30.67 % -16.85 % -6.44 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 57.03 % 138.12 % 79.52 % 144.14 % 145.12 %
Cash Flow Coverage Ratios TTM -239.51 % 207.5 % -49.48 % 157.08 % -185.98 % -428.57 %
Price To Free Cash Flows Ratio TTM -2.09 38.52 -92.27 22.18 -141.85 -188.58
Price To Operating Cash Flows Ratio TTM -2.01 22.3 -127.67 17.64 -203.89 -272.4
Price Cash Flow Ratio TTM -2.01 22.3 -127.67 17.64 -203.89 -272.4
Income Statement (TTM)
CHRO NVO VRTX REGN SGEN ARGX
Revenue $0B $232.26B $9.87B $13.12B $1.96B $1.23B
Gross Profit $-0B $196.5B $8.61B $11.3B $1.55B $1.11B
Gross Profit Ratio 0% 84.6% 87.21% 86.16% 79.1% 90.39%
EBITDA $-0.01B $113.33B $4.61B $4.69B $-0.62B $-0.22B
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-0.3B
EPS Diluted -1.28 9.31 13.89 34.77 -3.3 -5.16
Balance Sheet (MRQ)
CHRO NVO VRTX REGN SGEN ARGX
Long Term Debt $0B $20.53B $0.72B $2.7B $0.04B $0.02B
Total Liabilities $0.01B $207.93B $5.15B $7.11B $0.87B $0.44B
Total Equity $-0.01B $106.56B $17.58B $25.97B $2.8B $4.1B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $1.18B
Total Debt $0B $27.01B $0.81B $2.7B $0.04B $0.02B
Total Assets $0B $314.49B $22.73B $33.08B $3.67B $4.54B
Cash Flow Statement (TTM)
CHRO NVO VRTX REGN SGEN ARGX
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-0.43B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $-0.08B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0B $108.91B $3.54B $4.59B $-0.45B $-0.42B
Capital Expenditure $0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.04B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.98
ABCL AbCellera Biologics Inc. 2.97
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.21
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.65
ABPWW 0.0625
ABSI Absci Corporation 2.9
ABUS Arbutus Biopharma Corporation 3.2
ABVC ABVC BioPharma, Inc. 0.54
ABVX Abivax SA American Depositary Shares 6.16
ACAD ACADIA Pharmaceuticals Inc. 17.57
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.92
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.14
ACHV Achieve Life Sciences, Inc. 3.09
ACIU AC Immune SA 2.68
ACLX Arcellx, Inc. 66.48
ACRV Acrivon Therapeutics, Inc. Common Stock 5.74
Unlock